Đang chuẩn bị nút TẢI XUỐNG, xin hãy chờ
Tải xuống
Tuyển tập các báo cáo nghiên cứu về y học được đăng trên tạp chí y học Wertheim cung cấp cho các bạn kiến thức về ngành y đề tài: Fosamprenavir or atazanavir once daily boosted with ritonavir 100 mg, plus tenofovir/emtricitabine, for the initial treatment of HIV infection: 48-week results of ALERT. | AIDS Research and Therapy BioMed Central Research Fosamprenavir or atazanavir once daily boosted with ritonavir 100 mg plus tenofovir emtricitabine for the initial treatment of HIV infection 48-week results of ALERT Kimberly Y Smith 1 Winkler G Weinberg12 Edwin DeJesus3 Margaret A Fischl4 Qiming Liao5 Lisa L Ross5 Gary E Pakes5 Keith A Pappa5 C Tracey Lancaster5 for the ALERT COL103952 Study Team Open Access Address Section of Infectious Diseases Rush University Medical Center Chicago Illinois USA 2Infectious Diseases Service Kaiser Permanente Atlanta Georgia USA 3Orlando Immunology Center Research Facility Orlando Immunology Center Orlando Florida USA 4AIDS Clinical Research Unit University of Miami Miami Florida USA and 5Infectious Diseases GlaxoSmithKline Research Triangle Park North Carolina USA Email Kimberly Y Smith - Kimberly_Y_Smith@rush.edu Winkler G Weinberg - Winkler.Weinberg@kp.org Edwin DeJesus - edejesus@oicorlando.com Margaret A Fischl - mfactg@gate.net Qiming Liao - qiming.m.liao@gsk.com Lisa L Ross - lisa.l.ross@gsk.com Gary E Pakes - gary.e.pakes@gsk.com Keith A Pappa - keith.a.pappa@gsk.com C Tracey Lancaster - tracey.lancaster@yahoo.com Corresponding author fEqual contributors Published 28 March 2008 Received 29 November 2007 AIDS Research and Therapy 2008 5 5 doi 10.1186 1742-6405-5-5 Accepted 28 March 2008 This article is available from http www.aidsrestherapy.cOm content 5 1 5 2008 Smith et al licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License http creativecommons.org licenses by 2.0 which permits unrestricted use distribution and reproduction in any medium provided the original work is properly cited. Abstract Background Once-daily QD ritonavir 100 mg-boosted fosamprenavir 1400 mg FPV r100 or atazanavir 300 mg ATV r100 plus tenofovir emtricitabine TDF FTC 300 mg 200 mg have not been compared as initial antiretroviral treatment. To address this data gap we .
